EUROPEAN INSTITUTE OF ONCOLOGY

THE FIRC INSTITUTE OF MOLECULAR ONCOLOGY

FIRST IEO-IFOM MEETING ON CANCER

Milan (Italy), March 11-14, 2004

MARCH 11, 2004

SESSION 1
Signal Transduction
H. 3.00/8.00 pm

H. 3.00/3.30 pm
Julian Downward
Cancer Research UK London Research Institute. South Mimms, UK.
"Ras signalling pathways involved in cell survival and transformation"

H. 3.30/3.45 pm
Stefano Biffo
Molecular Biology and Functional Genomics. University of Eastern Piedmont & DIBIT-HSR. Italy.
"Translation of Extracellular Signals into Protein Synthesis: Finding the Interpreters"

H. 3.45/4.00 pm
Caroline Bouchard
Philipps University of Marburg. Germany
"*PKB/Akt-dependent phosphorylation of FoxO proteins mediates co-operativity between Myc and Ras in cellular transformation"*

H. 4.00/4.30 pm
Yosef Yarden
Dept. of Biological Regulation. The Weizmann Institute of Science. Rehovot, Israel.
"Oncogenic receptor tyrosine kinases: Signaling mechanisms and opportunities for cancer therapy"

H. 4.30/5.00 pm
Napoleone Ferrara
Molecular Oncology. Genentech. San Francisco, USA.
"VEGF: basic science and clinical progress"

H. 5.00/5.30 pm Coffee break

H. 5.30/5.45 pm
Silvia Giordano
Dept. of Oncological Sciences. University of Torino. Italy
"Sema4D induces angiogenesis through Met recruitment by Plexin B1"

H. 5.45/6.00 pm
Sabine Elowe
Samuel Lunenfeld Research Institute. Canada.
"Regulation of MAPK signalling by the Eph family of Receptor Tyrosine Kinases through Differential Recruitment of Shc"

H. 6.00/6.30 pm
Filippo G. Giancotti
Cell Biology Program. Memorial Sloan-Kettering Cancer Center. New York, USA.
"Adhesion Receptor Signaling during Tumor Progression"

H. 6.30/7.00 pm
Joan Massague
Cancer Biology and Genetics. Howard Hughes Medical Institute. Memorial Sloan-Kettering Cancer Center. New York, USA.
"Metastatic signals"

H. 7.00/7.15 pm
Alberto Bardelli
Sidney Kimmel Comprehensive Cancer Center. John Hopkins University. USA
"Mutational Analysis of Colorectal Cancer Genomes"

H. 7.15/7.30 pm
Soeren Jensby Nielsen
Molecular Cell Biology, BioImage A/S Denmark
"Novel Small-Molecule AKT Pathway Inhibitors Discovered by Redistribution®-Based High-Throughput Screening"

MARCH 12, 2004

SESSION 2
Angiogenesis and Metastasis
H. 9.00 am/1.00 pm

H. 9.00/9.30 am
Christer Betsholtz
Dept. of Medical Biochemistry. Goteborg University. Sweden.
"Mechanisms of developmental and pathological angiogenesis"

H. 9.30/10.00 am
David Shima
Eyetech Pharmaceuticals. Boston, USA.
"Multiple, distinct cues provided by the VEGF-A isoforms drive vascular development and disease"

H. 10.00/10. 15 am
Douglas Lowy
Lab Cellular Oncology. National Cancer Institute-NHI. USA
"E-Cadherin: a tumor suppressor that inhibits the ligand-dependent activation of many receptor tyrosine kinases"

H. 10.15/10.30 am
Enrico Giraudo
Dept. of Biochemistry, Diabetes and Comprehensive Cancer Centers. University of California at San Fransisco. USA.
"A bisphosphonate inhibits angiogenesis and impairs cervical carcinogenesis by targeting MMP-9 activity and its expression in infiltrating macrophages"

H. 10.30/11.00 am
Didier Stanier
Biochemistry and Biophysics, University of California. San Francisco, USA.
"Angiogenesis and epithelial development in zebrafish"

H. 11.00/11.30 am Coffee Break

H. 11.30 am/12.00 pm
Douglas Hanahan
Biochemistry and Biophysics, University of California. San Fransisco, USA.
"Tumor angiogenesis: mechanisms and therapeutic targeting"

H. 12.00/12.15 pm
Guido W. M. Swart
161 Biochemistry. NCMLS. University of Nijmegen. The Netherlands.
"From Activated Leukocyte Cell Adhesion Molecule to Melanoma Metastasis"

H. 12.15/12.30 pm
Daniel Peeper
Molecular Genetics. Netherlands Cancer Institute. The Netherlands.
"A genome-wide anoikis suppression screen identifies a potent inducer of metastasis"

H. 1.00 pm Lunch at IFOM

SESSION 3
Genomic Instability and Cell Cycle Checkpoints
H. 3.00/8.00 pm

H. 3.00/3.30 pm
Tomas Lindahl
Cancer Research UK London Research Institute. South Mimms, UK.
"Repair of endogenous DNA damage"

H. 3.30/4.00 pm
Jiri Bartek
Department of Cell Cycle and Cancer. Institute of Cancer Biology. Danish Cancer Society. Copenhagen, Denmark.
"DNA integrity checkpoints: mechanisms and cancer-predisposing defects"

H. 4.00/4.15 pm
Giannino Del Sal
Molecular Oncology LNCIB. Italy
"Dissecting the p73 apoptotic pathway: Pin1 links the activities of c-Abl and p300 in regulating p73 functions"

H. 4.15/4.30 pm
Vincenzo Costanzo
Genetics and Development. Columbia University. USA
"MRE11 promotes ATM activation by tethering DNA double-strand breaks together"

H. 4.30/5.00 pm
Jan Hoeijmakers
Institute of Genetics. Erasmus University. Rotterdam, The Netherlands.
"DNA damage and repair: the relationship with cancer and ageing"

H. 5.00/5.30 pm Coffee break

H. 5.30/6.00 pm
Graeme Smith
KuDos Pharmaceuticals, UK.
"Small molecule inhibitors of DNA repair pathways as a strategy to treat cancer"

H. 6.00/6.15 pm
Nadel Bertrand
Centre d'Immunologie de Marseille-Luminy, France.
"V(D)J-mediated Transposition of Signal Joints and Genomic Instability in Lymphoid Cells"

H. 6.15/6.30 pm
Domenico Grieco
Dept. of Molecular and Cellular Biology and Pathology. University of Napoli. Italy.
"Role for cyclin-dependent kinase 1 activity regulation in coordinating late mitotic events"

H. 6.30/7.00 pm
Erich Nigg
Max-Planck Institute for Biochemistry. Dept. of Cell Biology. Martinsried, Germany:
"Cell division and chromosomal instability"

H. 7.00/7.15 pm
Giordano Liberi
FIRC Institute of Molecular Oncology, Milan, Italy
"Sgs1, the yeast BLM orthologue, prevents recombination at damaged replication forks"

MARCH 13, 2004

SESSION 4
Aging and Senescence
H. 9.00 am/1.00 pm

H. 9.00/9.30 am
Titia de Lange
Lab for Cell Biology and Genetics. Rockefeller University. New York, USA.
"Protection of human chromosome end"

H. 9.30/10.00 am
Jerry W. Shay
Dept. Of Cell Biology. University of Texas Southwestern Medical Center. Dallas, USA.
"Targeting Telomerase for Cancer Therapeutics"

H. 10.00/10.15 am
Klas Wiman
Cancer Center Karolinska. Sweden.
"Reactivation of mutant p53 by small molecules: a novel strategy for cancer therapy"

H. 10.15/10.30 am
Emanuela Colombo
Dept. of Experimental Oncology. European Institute of Oncology. Italy.
"Study of the physiological role of Nucleophosmin (NPM) through the analysis of the knocked-out mouse"

H. 10.30/11.00 am
Gordon Peters
Molecular Oncology Laboratory. London Research Institute. Lincoln's Inn Fields Laboratories. London, UK.
"The consequences of p16INK4a deficiency in human cells"

H. 11.00/11.30 am Coffee break

H. 11.30/11.45 am
Rossella Galli
Stem Cell Research Institute. DIBIT-HSR. Italy.
"Prospective isolation, cloning and characterization of long-term expanding, tumor-founding neural stem cells from human glioblastomas"

H. 11.45 am/12.15 pm
Scott Lowe
Cold Spring Harbor Laboratory's Cancer Center. USA.
"Tumor Suppression Involving the p53 and Rb Pathways"

H. 12.15/12.30 pm
Marikki Laiho
Haartman Institute. University of Helsinki. Finland.
"NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation"

H. 12.30/13.00 pm
Pier Giuseppe Pelicci
Dept. of Experimental Oncology. European Institute of Oncology. Italy.
"The p53-p66Shc Signaling Pathway in Tumor Suppression and Life Span Control"

H. 1.00 pm Lunch at IFOM

SESSION 5
Animal Models
H. 2.00/8.00 pm

H. 2.00/4.00 pm Poster Session

H. 4.00/4.30 pm Coffee Break

H. 4.30/5.00 pm
Mariano Barbacid
Spanish National Cancer Center. Madrid, Spain.
"Cell Cycle and Cancer: Reassessing the Role of Cyclin Dependent Kinases"

H. 5.00/5.30 pm
EMBO Lecture
Anton Berns
Division of Molecular Genetics and Center for Biomedical Genetics. The Netherlands Cancer Institute. Amsterdam, The Netherlands.
"Conditional mouse models for cancer"

H. 5.30/6.00 pm
Eric Holland
Molecular Departments of Neurosurgery, Neurology and Cell Biology. Memorial Sloan-Kettering Cancer Center. New York, USA.
"Preclinical mouse models of glioma"

H. 6.00/6.30 pm
Alan Balmain
Cancer Research Institute and Biochemistry. University of California. San Francisco, USA.
"Cancer susceptibility: from mouse models to humans"

H. 6.30/.6.45 pm
Alma Dhawahir
Spanish National Cancer Center. Spain.
"Genetic analysis of the role of K-Ras in vivo"

H. 6.45/7.15 pm
Peter Carmeliet
Center for Transgene Technology and Gene Therapy. Flanders Interuniversity Institute for Biotechnology. University of Leuven. Belgium.
"Functional angiogenomics"

MARCH 14, 2004

SESSION 6
Epigenetic Mechanisms in Cancer
H. 9.00 am/1.00 pm

H. 9.00/9.30 am
Moshe Yaniv
Developmental Biology Dept. Institut Pasteur. Paris, France.
"Chromatin remodeling complexes and cell proliferation"

H. 9.30/10.00 am
Amanda Fisher
Lymphocyte Development Group. MCR. Clinical Sciences Center. London, UK.
"Chromatin and lineage restriction"

H. 10.00/10.15 am
Valerio Orlando
Dulbecco Telethon Institute. Institute of Genetics and Biophysics National Research Counsil. Italy
"Mechanisms of epigenome reprogramming and control of cell identity by Polycomb proteins and non-coding RNA"

H. 10.15/10.30 am
Merel Lingbeek
The Netherlands Cancer Institute. Amsterdam, The Netherlands.
"Bmi1 acts downstream of Shh signaling in cerebellar development and is overexpressed in human medulloblastomas"

H. 10.30/11.00 am
Tony Kouzarides
Cancer Research UK laboratories. Cancer Research Uk Institute. University of Cambridge. Cambridge, UK.
"Role of histone modifications in chromatin control"

H. 11.00/11.30 am Coffee break

H. 11.30 am/12.00 pm
Peter Jones
Norris Comprehensive Cancer Center. Keek School of Medicine. University of Southern California. Los Angeles, USA.
"Epigenetic Therapy"

H. 12.00/12.15 pm
Diego Pasini
Dept. of Experimental Oncology. European Institute of Oncology, Milan, Italy
"The Polycomb group protein Suz12 is essential for mouse development and Histone Methyl Transferase activity of the PRC2 complex"

H. 12.15/12.45 pm
Thomas Jenuwein
Research Institute of Molecular Pathology. Vienna, Austria.
"The indexing potential of histone lysine methylation"

H. 12.45/1.00 pm
Massimo Levrero
Fondazione A Cesalpino La Sapienza.University of Rome. Italy.
"Class III and class I histone deacety lases (hdacs) inhibitors cooperate with dna damaging chemotherapeutic drugs to induce p73-dependent apoptotic pathways in hcc cells"

END OF THE MEETING